secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-04-19T23:59:59+00:00
Accession:  0000950170-23-013370
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports Phase 1b data for ERAS-601+cetuximab; MTD 40mg BID; tolerable safety
--------------------------------------------------------------------------------

- Promising initial safety from Phase 1b FLAGSHP-1 dose escalation for ERAS-601 + cetuximab in advanced solid tumors.
- Only Grade 1-2 TRAEs at or below the combination MTD; ERAS-601 MTD 40 mg BID 3/1 with cetuximab 500 mg/m2 Q2W.
- Data presented at AACR 2023; expects initial Phase 1b dose expansion data in HPV-negative HNSCC in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023013370/0000950170-23-013370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023013370/eras-20230418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer